EXAS

NEUTRALM&A

Exact Sciences Corporation

2026-03-04

Price

$103.50

+0.13%

Score5.5Watchlist

Signals5/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 9

Volume0.9xvs 20d avg

Analysis

EXAS is currently trading as a high-confidence merger arbitrage play, effectively tethered to Abbott Laboratories' (ABT) acquisition offer of $105.00 per share. The 'Quiet Storm' and 'Steady Climb' signals are not traditional breakouts but rather the low-volatility compression characteristic of a stock awaiting a definitive deal close in Q2 2026. With shareholders approving the merger on Feb 20 and HSR waiting periods expired, the stock's resilience in a 'Risk-Off' macro regime confirms it is functioning as a defensive cash-equivalent proxy.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACK

Key Takeaways

**M&A Anchor:** Price action is dictated by the $1.50 spread (1.4%) to the $105 deal price, not organic discovery.
**Regulatory De-Risking:** The expiration of the HSR waiting period and recent shareholder approval remove the primary deal-break risks.
**Defensive Utility:** In the current 'Fear vs. Function' divergence, EXAS acts as a safe haven, decoupled from the broader market's volatility.

← Back to 2026-03-04 View Full EXAS History →Yahoo Finance &nearr;